

**REMARKS**

Claims 1-6, 63-68, and 71 are pending in the present application. Claims 7-62, 69, 70, and 72 have been cancelled without prejudice to or disclaimer of the subject matter contained therein. Claims 2-6, 67, 68, and 71 have been amended. The amendments to the claims are supported by the original claims and specification. No new matter has been added by way of amendment.

The specification has been amended to identify the present application as a U.S national stage filing of PCT/US2004/19692 and to substitute an abstract on a separate sheet in accordance with U.S. practice.

## CONCLUSION

Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to effect the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,



Kathryn L. Coulter  
Patent Attorney  
Registration No. 45,889

Date: December 13, 2005  
GlaxoSmithKline  
Five Moore Drive, PO Box 13398  
Research Triangle Park, North Carolina 27709  
Telephone: (919) 483-1467  
Facsimile: (919) 483-7988